Gabriel N Hortobagyi Selected Research

Doxorubicin (Adriamycin)

1/2022	Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer.
10/2020	Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221).
12/2019	Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
1/2019	Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study.
1/2018	Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial.
11/2015	Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis.
1/2015	SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.
12/2014	Outcomes of children exposed in utero to chemotherapy for breast cancer.
12/2011	Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221).
3/2011	Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gabriel N Hortobagyi Research Topics

Disease

419	Breast Neoplasms (Breast Cancer) 10/2022 - 01/2002
268	Neoplasms (Cancer) 01/2022 - 01/2002
64	Neoplasm Metastasis (Metastasis) 05/2021 - 06/2002
43	Pathologic Complete Response 01/2022 - 06/2005
27	Triple Negative Breast Neoplasms 01/2022 - 03/2008
22	Disease Progression 12/2021 - 04/2002
16	Inflammatory Breast Neoplasms 10/2021 - 01/2003
12	Residual Neoplasm 01/2018 - 04/2004
11	Circulating Neoplastic Cells 01/2022 - 03/2005
9	Cardiotoxicity 10/2021 - 11/2002
7	Neutropenia 01/2019 - 07/2003
6	Ovarian Neoplasms (Ovarian Cancer) 01/2019 - 11/2002
6	Carcinogenesis 07/2014 - 03/2004
5	Obesity 10/2021 - 09/2008
5	Infections 05/2021 - 10/2002
5	Peripheral Nervous System Diseases (PNS Diseases) 11/2018 - 11/2012
5	Noninfiltrating Intraductal Carcinoma (DCIS) 10/2014 - 06/2002
5	Heart Failure 11/2013 - 11/2002
4	Fatigue 01/2019 - 02/2004
4	Febrile Neutropenia 01/2019 - 01/2003
4	Pain (Aches) 01/2016 - 06/2002

Drug/Important Bio-Agent (IBA)

78	Hormones (Hormone)IBA 10/2022 - 10/2002
69	Estrogen ReceptorsIBA 11/2021 - 01/2002
48	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 01/2002
46	AnthracyclinesIBA 10/2021 - 02/2002
45	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 01/2002
42	Trastuzumab (Herceptin)FDA Link 12/2019 - 04/2002
38	Paclitaxel (Taxol)FDA LinkGeneric 10/2020 - 05/2002
34	Biomarkers (Surrogate Marker)IBA 12/2019 - 06/2002
34	Fluorouracil (Carac)FDA LinkGeneric 01/2019 - 01/2002
33	human ERBB2 proteinIBA 10/2022 - 01/2004
32	taxaneIBA 11/2018 - 02/2002
31	Proteins (Proteins, Gene)FDA Link 09/2017 - 09/2003
30	Progesterone Receptors (Progesterone Receptor)IBA 10/2020 - 10/2002
25	ErbB Receptors (EGF Receptor)IBA 12/2021 - 10/2002
19	Pharmaceutical PreparationsIBA 01/2021 - 06/2002
19	Tamoxifen FDA LinkGeneric 01/2020 - 01/2002
19	Docetaxel (Taxotere)FDA Link 04/2014 - 01/2002
18	Everolimus FDA Link 01/2022 - 10/2007
17	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 03/2004
17	Biological ProductsIBA 01/2017 - 10/2002
16	Aromatase InhibitorsIBA 01/2019 - 03/2004
16	Taxoids (Taxanes)IBA 10/2015 - 05/2002
15	Estrogens (Estrogen)FDA Link 01/2020 - 07/2003
15	exemestane (Aromasin)FDA Link 01/2019 - 03/2004
12	Diphosphonates (Bisphosphonates)IBA 05/2021 - 10/2003
12	Epidermal Growth Factor (EGF)IBA 10/2020 - 10/2007
12	Messenger RNA (mRNA)IBA 09/2017 - 06/2005
11	Phosphotransferases (Kinase)IBA 01/2019 - 05/2003
9	Zoledronic Acid (Zometa)FDA Link 05/2021 - 01/2005
9	Capecitabine (Xeloda)FDA Link 03/2012 - 09/2003
8	Anastrozole (Arimidex)FDA LinkGeneric 01/2022 - 06/2002
8	Bevacizumab (Avastin)FDA Link 01/2018 - 10/2004
8	Lapatinib (GW572016)FDA Link 07/2014 - 07/2008
7	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022 - 04/2004
7	Monoclonal AntibodiesIBA 01/2022 - 06/2002
7	RNA (Ribonucleic Acid)IBA 10/2021 - 06/2003
7	Immune Checkpoint InhibitorsIBA 01/2021 - 07/2017
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2019 - 08/2007
7	Indicators and Reagents (Reagents)IBA 01/2019 - 11/2002
7	Epirubicin (Ellence)FDA LinkGeneric 11/2015 - 06/2005
7	Tyrosine Kinase InhibitorsIBA 07/2014 - 06/2003
6	Letrozole (Femara)FDA LinkGeneric 10/2022 - 11/2016
6	ribociclibIBA 10/2022 - 11/2016
6	LigandsIBA 01/2021 - 12/2009
6	Biological FactorsIBA 10/2020 - 07/2016
6	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2020 - 07/2015
6	ParaffinIBA 12/2019 - 04/2004
6	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2019 - 10/2006
6	Tumor Biomarkers (Tumor Markers)IBA 10/2014 - 10/2002
6	Transcription Factors (Transcription Factor)IBA 02/2012 - 09/2003
5	Phenobarbital (Luminal)FDA Link 11/2019 - 08/2005
5	Antineoplastic Agents (Antineoplastics)IBA 01/2019 - 01/2007
5	Metformin (Glucophage)FDA LinkGeneric 01/2019 - 07/2009
5	ixabepilone (BMS 247550)FDA Link 10/2015 - 08/2007
5	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 03/2011 - 01/2002
5	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2011 - 06/2007
4	Fulvestrant (Faslodex)FDA Link 01/2022 - 08/2012
4	CytokinesIBA 01/2021 - 02/2004
4	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2020 - 01/2013
4	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2019 - 01/2008
4	Methotrexate (Mexate)FDA LinkGeneric 01/2019 - 11/2003
4	TOR Serine-Threonine KinasesIBA 01/2019 - 02/2012
4	Tyrosine (L-Tyrosine)FDA Link 01/2019 - 08/2007
4	Gemcitabine FDA Link 01/2018 - 05/2002
4	Cyclin EIBA 06/2017 - 11/2002
4	Dasatinib (BMS 354825)FDA Link 12/2016 - 05/2010
4	Selective Estrogen Receptor Modulators (SERM)IBA 01/2016 - 03/2004
4	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 12/2015 - 05/2005
4	Vinorelbine (Navelbine)FDA LinkGeneric 01/2014 - 01/2002

Therapy/Procedure

186	Therapeutics 10/2022 - 01/2002
154	Drug Therapy (Chemotherapy) 12/2021 - 01/2002
78	Neoadjuvant Therapy 01/2022 - 01/2002
32	Radiotherapy 10/2021 - 06/2002
31	Adjuvant Chemotherapy 12/2019 - 01/2002
15	Mastectomy (Mammectomy) 06/2014 - 01/2002
11	Segmental Mastectomy (Lumpectomy) 10/2021 - 07/2002
8	Aftercare (After-Treatment) 01/2021 - 07/2002
4	Precision Medicine 01/2021 - 11/2006
4	Prophylactic Mastectomy 10/2014 - 12/2007